The combination of the PARP inhibitor talazoparib and the immune checkpoint inhibitor atezolizumab as maintenance therapy significantly improved the progression-free survival (PFS) of patients with SLFN11-positive small cell lung cancer (SCLC) (39). The gene discussed is PARP1; the disease is small cell lung carcinoma.